# Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

> **NCT03414489** · — · NO_LONGER_AVAILABLE · sponsor: **RedHill Biopharma Limited**

## Conditions studied

- Cholangiocarcinoma
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma, Perihilar
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinoma, Intrahepatic

## Interventions

- **DRUG:** ABC294640

## Key facts

- **NCT ID:** NCT03414489
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03414489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03414489, "Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03414489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*